Regentis Biomaterials News
10 articles
Growth-Positive
Regentis Biomaterials Combining with OceanTech Acquisitions I in $95M Deal | DealFlow's SPAC News
OceanTech Acquisitions I has announced a definitive merger agreement with Israel-based Regentis Biomaterials at a $95 million valuation. The all-stock deal will see Regentis shareholders receive $95 million of OceanTech shares. Regentis is a regenerative medicine company developing tissue repair solutions, currently focusing on orthopedic treatments using its Gelrin platform. OceanTech has previously made two unsuccessful merger attempts and underwent a complete change in management in March. The SPAC raised $100 million in a May 2021 IPO with initial plans to target marine and IT industries.
AcquisitionManagement Changes
Regentis Biomaterials Ltd to Become Publicly Listed on Nasdaq via Business Combination with OceanTech Acquisitions I Corp.
growth-positive
TRIA Orthopedics First in Minnesota to Test Breakthrough GelrinC™ Implant to Regenerate Knee Cartilage
Regentis Biomaterials announced that TRIA Orthopedics is the first in Minnesota to use the GelrinC implant to treat damaged articular cartilage causing knee pain. GelrinC is being evaluated as a treatment to help the body regrow cartilage in the knee. The current standard of care is microfracture, which provides only short-term relief. GelrinC, on the other hand, requires only a single minimally invasive procedure and may promote long-term repair of the cartilage. The GelrinC implant is part of the SAGE clinical trial, which is comparing GelrinC to microfracture. Regentis Biomaterials is a privately held company focused on developing hydrogels for tissue regeneration.
Customers
Regentis Biomaterials Expands SAGE Clinical Trial of GelrinC™ for Knee Pain
growth-positive
Regentis Biomaterials Performs the First Cases in Gelrinc Pivotal Study
Regentis Biomaterials has started its Phase III pivotal clinical trial of GelrinC for the treatment of focal knee cartilage defects. The trial involves successful surgeries on three patients in the US and Denmark and aims to compare GelrinC to the current standard of care treatment. The trial will support a Pre-market Approval Application (PMA) to market GelrinC in the US. The procedures were performed by Dr. Jason Scopp and Dr. Bryan Huber in the US, and Dr. Martin Lind in Denmark. Regentis President and CEO Alastair Clemow stated that the success of the procedures is a significant milestone for the company and will help patients recover from damaged knee cartilage.
Customers
growth-positive
Regentis Biomaterials Receives European CE Mark Approval for GelrinC
Regentis Biomaterials has received European CE mark approval for its GelrinC biodegradable implant, allowing the company to access new global markets and help more patients with damaged articular knee cartilage. The approval expands upon the existing CE mark for a version containing denatured bovine-sourced fibrinogen. GelrinC is designed to treat articular knee cartilage defects and has shown positive results in clinical studies. Regentis is currently conducting a Phase III clinical trial in the US and Europe to support FDA approval. The company sees a potential market of over 150,000 procedures in the US alone.
Customers
growth-positive
Regentis Receives IDE Approval for Pivotal GelrinC Clinical Trial
Regentis Biomaterials has received FDA approval to initiate a Phase III clinical study of GelrinC, a treatment for focal cartilage defects in the knee. The cartilage repair market is estimated to be worth over $1 billion. The GelrinC procedure is easy and quick for surgeons to perform and can be carried out using a minimally invasive approach. The FDA trial will evaluate the safety and efficacy of GelrinC compared to a historical microfracture control arm. Regentis Biomaterials is a privately held company focused on developing and commercializing hydrogels for tissue regeneration.
Investment
growth-positive
Regentis Biomaterials raises $15m
Chinese pharmaceutical group Haisco led a $15 million Series D financing round in Israeli startup Regentis Biomaterials, bringing the total raised by the company to $35 million. Regentis Biomaterials develops products to treat damaged cartilage and is currently conducting clinical trials for its flagship product, GelrinC. The company already has approval for sale in Europe and plans to begin clinical trials for FDA approval in the US. The investment from Haisco and other existing investors will help Regentis Biomaterials expand its technological potential for the Chinese market.
Investment
growth-positive
Regentis Reports Articular Cartilage Repair
Regentis Biomaterials announces favorable clinical data for its GelrinC implant for treating articular cartilage in injured knees. The implant is a biodegradable hydrogel that degrades within 6-12 months and is replaced with functional and durable cartilage created by stem cells. A recent study showed substantial improvement in patient outcomes, with a 43% improvement in the Knee injury and Osteoarthritis Outcome Score (KOOS) and an 86% improvement in the subjective questionnaire. The GelrinC implant works in combination with the microfracture procedure to enhance the bodys ability to regenerate new cartilage. The company is focused on developing and commercializing proprietary hydrogels for tissue regeneration.
Customers
growth-positive
Investments allow further research, expansion for Regentis Biomaterials
Regentis Biomaterials Ltd. has received a $10 million investment to continue promoting GelrinC, a biodegradable implant that increases the growth of articular cartilage in damaged knee joints. The investment will also allow the company to expand its clinical efforts and demonstrate the effectiveness of GelrinC in regenerating cartilage. GelrinC is currently undergoing clinical trials and is not yet available in the United States, Europe, and Israel. The investment is expected to support the companys growth and help patients return to an active lifestyle.
InvestmentExpand
